Leonard Guarente, Dan Alminana, Eric Marcotulli, Andrew Lin, Thomas Wilhelm, Mark Morris, Jeremy Berger, Jonathan Fasig
2014
Private company
Series C
71.2
General Catalyst, ARCH Venture Partners, Breyer Capital, GISEV Family Office, Health IQ, Mayo Clinic Ventures, Morningside Ventures
Genomic instability
supplement
Phase 2 Trials
We translate critical scientific advancements into accessible products for consumers.
At Elysium, we’re focused on exploring compelling scientific advancements that have the potential to benefit everyone.